Biopharma company Corcept Therapeutics (NASDAQ: CORT) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 64% year on year to $340.5 million. The company expects the full year’s revenue to be around $1.15 billion, close to analysts’ estimates. Its non-GAAP profit of $1.01 per share was 20.2% above analysts’ consensus estimates.

Is now the time to buy CORT? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Corcept’s third quarter saw revenue growth and profitability that surpassed Wall Street expectations, but the market reacted negatively following the call. Management attributed the strong financial results to accelerating adoption of Lifyorli in ovarian cancer and continued growth in its endocrinology segment, particularly with Korlym and its authorized generic. CEO Joe Belanoff highlighted that Lifyorli’s rapid physician adoption was enabled by its mechanism of action and convenient oral administration, while the endocrinology business benefited from increasing awareness of hypercortisolism, supported by recent clinical findings and updated medical guidelines.

Looking forward, Corcept’s guidance is anchored by the expected continued uptake of Lifyorli and the potential launch of relacorilant for Cushing’s syndrome, pending regulatory decisions. Management pointed to upcoming pivotal trial readouts in oncology and liver disease, as well as growing medical community support for broader screening and treatment of hypercortisolism. President of Endocrinology Justin Gunn stated, “As ADA and AACE recommendations are incorporated, more patients will be screened, diagnosed, and treated, expanding our market.”

Key insights from management’s remarks

Management cited Lifyorli’s accelerating adoption, new clinical guidelines for hypercortisolism, and a broadened late-stage pipeline as primary contributors to the quarter’s performance and future outlook.

• Lifyorli’s rapid adoption: Management highlighted that more than 2,300 patients have been treated with Lifyorli since its launch, with repeat prescriptions and expansion to earlier lines of therapy driving further uptake. The drug’s differentiated mechanism and ease of administration have supported physician confidence, according to President of Oncology Roberto Vieira.
• Endocrinology momentum: Increased clinical recognition of hypercortisolism, informed by the CATALYST and MOMENTUM studies, has led to updated recommendations from leading medical societies. Management expects these guidelines to drive more widespread screening and treatment, expanding the addressable market for existing and future therapies.
• Pipeline advancements: The company reported progress in several late-stage studies, including pivotal trials for relacorilant in both Cushing’s syndrome and various solid tumors, as well as positive results from the phase IIb MONARCH study of miricorilant in metabolic dysfunction-associated steatohepatitis (MASH). These efforts are expected to broaden Corcept’s market reach if successful.
• Strategic focus on earlier intervention: Data from the BELLA trial indicate that using Lifyorli and related GR antagonists earlier in the course of treatment may deliver greater clinical benefit, particularly in ovarian cancer. This has informed the company’s strategy to pursue earlier-line indications and combination regimens.
• Expansion into new indications: Beyond current approvals, management is pursuing development in cancer immunotherapy combinations (SYNERGY study) and metabolic and neurological diseases such as ALS, reflecting a diversified late-stage pipeline.

Drivers of future performance

Corcept’s forward outlook centers on continued Lifyorli growth, expanded endocrinology screening, and pivotal pipeline readouts, while monitoring for regulatory outcomes and competitive developments.

• Pivotal readouts and regulatory decisions: The company’s near-term trajectory depends on the FDA’s decision on relacorilant for Cushing’s syndrome, expected by year-end, and on late-stage trial results in ovarian and pancreatic cancer, MASH, and ALS. Positive outcomes could substantially increase eligible patient populations.
• Broader disease awareness and guideline shifts: Management is counting on recent updates from the American Diabetes Association and American Association of Clinical Endocrinology to drive more routine screening and diagnosis of hypercortisolism. This could accelerate market expansion for both Korlym and future products, though the pace of adoption in clinical practice remains an uncertainty.
• Competitive and combination therapy landscape: As new entrants and alternative mechanisms emerge in ovarian cancer and related fields, Corcept’s ability to demonstrate additional benefit—especially in combination regimens—will be key. Management acknowledged the potential for combination studies with antibody-drug conjugates and immunotherapies, but noted that differentiation and market leadership will depend on real-world outcomes and integration into treatment algorithms.

Catalysts in upcoming quarters

In the next several quarters, our team will track (1) the FDA decision on relacorilant for Cushing’s syndrome, (2) pivotal trial readouts for relacorilant in ovarian, pancreatic, and endometrial cancer, as well as miricorilant in MASH, and (3) the integration of new screening guidelines for hypercortisolism into clinical practice. Progress in ALS and immunotherapy combination studies will also be important indicators of pipeline value.

Corcept currently trades at $79.63, down from $81.93 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

Now could be the perfect time to invest in these stocks

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.